trial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with increased mortality and morbidity. 1,2 Recentl meta-analyses have shown protective effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) on the risk of AF through attenuation of atrial remodeling. 3-7 However, there was considerable variation in the studies' demographics, baseline characteristics and duration of follow-up, so the protective effect of statins against the risk of AF was not consistent.
Hypertension (HTN) is the most frequent cause of AF and stroke, and is associated with a significant risk (odds ratio: 1.8) for the development of AF, and a population-attributable risk of 14%. 8, 9 Moreover, elderly patients are more likely to suffer from AF than younger patients. 8 Therefore, we hypothesized that statin therapy would have a protective effect against the risk of AF in elderly patients with HTN.
Recently, the development of echocardiographic technology that includes a feature-tracking method (Velocity Vector Imaging [VVI], Siemens, Mountain View, CA, USA) has enabled routine evaluation of left atrial (LA) phasic volume and function. 10 Using this technology, we recently conducted a prospective study of 580 adults and found that reduced LA phasic function independently predicted the risk of new-onset AF, suggesting an association between LA functional remodeling and AF. 11, 12 The aim of the present study was to determine whether a strong lipophilic statin (pitavastatin) has a beneficial effect on the prevention of new-onset AF in elderly patients with HTN and preserved LV ejection fraction (LVEF). In addition, our goal was to determine the relationships among statin treatment, the development of AF, and LA and LV structure and function.
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Methods

Subjects and Study Protocol
This was a non-randomized prospective study to elucidate the effect of pitavastatin (strong lipophilic statin) on new-onset AF, and LA and LV structure and function. We enrolled consecutive elderly patients (≥65 years old) with HTN, who were found to have established LV hypertrophy (LV mass index: ≥115 g/m 2 [male], ≥95 g/m 2 [female] 13 ) and preserved LVEF (≥50%) based on echocardiography. Exclusion criteria were the use of statins within the prior 6 months, mitral stenosis, moderate-to-severe mitral regurgitation, previous mitral valve surgery, permanent cardiac pacemaker implantation and existing atrial arrhythmias such as AF, atrial flutter or atrial tachycardia documented by ECG or Holter ECG. In addition, 12 subjects were excluded from the study because of poor echocardiographic recordings as a result of severe obesity or emphysema. We defined 2 groups according to the need for statin therapy based on the Japanese guidelines for the prevention of atherosclerotic disease (1-2 coronary risk factors: low-density lipoprotein cholesterol (LDL-C) level ≤140 mg/dl; 3-4 coronary risk factors: LDL-C level ≤120 mg/dl; or a history of ischemic heart disease: LDL-C level ≤100 mg/dl). We prospectively enrolled eligible consecutive patients until the number of patients reached 110 in both groups. A total of 710 consecutive patients were screened by echocardiography from January until April in 2010 and then, 110 patients with HTN who needed statin therapy (HTN with statin group: age, 75±5 years) were started on pitavastatin (1-2 mg/day) in addition to appropriate medication for HTN. The other 110 patients with HTN but not requiring statin therapy (HTN without statin group: age, 75±5 years) continued on their medications for HTN. In a previous meta-analysis, the risk of AF was 17.4% within 6 months in control group with risk factors for AF such as coronary heart disease, and risk reduction by statin therapy was 0.39. 14 Another meta-analysis reported that the risk of AF was 12.4% within 3 months in control group with risk factors for AF and risk reduction by statin therapy was 0.61. 3 There was no report on the risk of AF in elderly patients with HTN and established LV hypertrophy. Therefore, to determine the number of the enrolled patients we hypothesized that the risk of AF would be 20% during 2 years in control group and risk reduction by statin therapy would be 0.5 with reference to the previous 2 meta-analyses. Blood samples were collected, and echocardiog- Medical therapy was also evaluated in each patient. We performed monthly ECG examinations of all the enrolled patients, regardless of symptoms of arrhythmia during the follow-up period. All patients who had palpitations and/or symptoms of arrhythmia underwent both ECG and Holter ECG examinations to confirm new-onset AF. The development of new-onset AF was confirmed by Holter ECG examination in all patients. We defined the time of development of AF as the month when the Holter ECG confirmed the presence of AF.
The study was approved by the institutional ethics committee and informed consent was given by all patients before en-rollment.
Echocardiography
Transthoracic echocardiography was performed using an ACU-SON sequoia 512 (Siemens) ultrasound system with ultrasound transducer at 4V1c (1.5-4.25 MHz) to evaluate LA function. LA volumes were measured during a single cardiac cycle using feature-tracking echocardiography and on-line software (Syngo VVI, Siemens). The reliability of the feature-tracking echocardiographic method for the quantification of LA function has been established in previous studies. 10,12 With this method, the endocardial border of the LA is visually identified and manually outlined by the examiner. The manually placed endocardial tracing over 1 frame is then automatically tracked throughout the cardiac cycle. The software allows editing of the initial trace and the endocardial velocity is derived as the ratio between frame-to-frame displacement and the time interval. The velocity vectors in the 2-dimensional plane are displayed throughout the cardiac cycle, representing displacement of the speckles in relation to each other along the endocardial contour of the LA. Because VVI is an endocardial border tracking technique, it is possible to track the movement of a thin-walled structure such as the LA. Using this method, a time-LA vol-ume (V) curve and strain rate (SR) can be automatically and promptly provided (Figures 1A,B ). Maximum LAV, minimum LAV and LAV just before atrial contraction were obtained from the apical 4-chamber view by VVI with a frame rate of 55-60 frames/s using Simpson's method (Figures 1C,D) . LA total EF (reservoir function), passive EF (conduit function) and active EF (booster pump function) were calculated to evaluate phasic LA function. LA total, passive and active EF during a cardiac cycle were defined as (maximum LAV-minimum LAV)/ maximum LAV×100%, (maximum LAV-pre-atrial contraction LAV)/maximum LAV×100% and (pre-atrial contraction LAV-minimum LAV)/pre-atrial contraction LAV×100%, respectively. To evaluate phasic LA function, LA peak SRs during systole, early diastole and atrial contraction were also obtained from the LA mid-septal and mid-lateral walls. Average SR values from the mid-septal and mid-lateral walls were used in the analysis. Moreover, LA peak strain was obtained from the average of the LA mid-septal and mid-lateral wall strains. Several conventional echocardiographic parameters were also measured according to standard echocardiographic methods. 13 LVEF was assessed as a traditional index of LV systolic function. LA dimension and LV mass were also assessed, and the ratio of early diastolic transmitral inflow velocity to annular tissue velocity (E/e') was measured as an index of diastolic function. The maximum LAV index, pre-atrial contraction LAV index and minimum LAV index were calculated by dividing each of these measurements by body surface area.
Statistical Analysis
The data are expressed as the mean ±1 standard deviation. Categorical data are summarized as percentages and compared with a chi-square test. Comparisons of echocardiographic parameters between baseline and follow-up in each group were per- formed by paired t-tests; comparisons of parameters between the 2 groups were performed by unpaired t-tests. A P value <0.05 was considered significant. In the protocol, the assumptions of sample size (110 control/treatment groups) were performed with a 5% alpha error rate and 10% beta error rate for a 2-sided test to detect the risk reduction by statin therapy of 0.5. Survival curves were plotted by the Kaplan-Meier method and hazard ratios were calculated by univariate Cox regression analysis. Multivariate Cox regression analysis was performed using parameters with a P value <0.05 in the univariate analysis to determine the independent predictors of new-onset AF. We performed multivariate analysis using 2 models. Model 1 included parameters at baseline. Model 2 included the difference over 1 year of the parameters. Statistical analyses were performed using Stat View version 5.0 (SAS Institution, Cary, NC, USA).
Results
Patients' Characteristics
All participants were followed up for approximately 2 years and did not develop any serious diseases. Patients' clinical characteristics at baseline are shown in Table 1 . During a follow-up period of 23 months (median: 23 months, 25th percentile: 21 months, 75th percentile: 24 months), 20 of 220 (9.0%) subjects developed ECG-confirmed new-onset AF (0-12 months: n=7, 13-24 months: n=13). There were no significant differences between the 2 in the clinical, laboratory or echocardiographic parameters groups at baseline, except for LDL-C levels ( Table 2) . Patients receiving pitavastatin had higher baseline LDL-C levels than those not receiving pitavastatin (146±14 mg/dl and 103±16 mg/dl, respectively, P<0.001). After pitavastatin therapy, LDL-C decreased to levels similar to those in untreated patients (102±16 mg/dl and 103±18 mg/dl, respectively, P=0.77) ( Table 2) .
Echocardiographic Parameters of LV and LA Structure and Function
The time-LAV curve was easily and quickly obtained using VVI in all cases (Figure 1) . Echocardiographic parameters in HTN patients with and without statin therapy are shown in Table 2 . There was no significant difference between the 2 groups in the percentage of patients with LVEF ≥50% at baseline and after 1 year of follow-up. LV mass index in the HTN with statin group was significantly decreased by 6% after 1 year despite no difference between the 2 groups in the blood Data are presented as the number (%) of patients or the mean ± SD. AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitors; CAD, coronary artery disease; CCB, calcium-channel blocker. Other abbreviations as in Table 2 . WARITA S et al.
pressure reduction from baseline to 1 year. LA volume and function in the HTN patients treated with pitavastatin improved more than in HTN patients not treated with pitavastatin and this was associated with regression of hypertrophy and improvement of diastolic function despite no difference between the 2 groups in LDL-C levels and blood pressure after 1 year (Table 2 and Figures 2,3) .
Development of New-Onset AF
There was a significantly lower rate of developing new-onset AF in the HTN patients treated with a statin (n=5) than in the HTN patients not treated with a statin (n=15) over the 2 years of follow-up (P=0.019). Clinical and echocardiographic parameters in patients with and without the development of newonset AF are shown in Table 3 . Kaplan-Meier curves in Figure 4 show the difference in cumulative survival free of new-onset AF after baseline in the patients with and without statin therapy (univariate Cox regression analysis: hazard ratio: 0.32, 95% confidence interval 0.12-0.88, P=0.027). We performed multivariate Cox regression analysis to elucidate the independent predictors of new-onset AF in both groups. However, the LA maximum and minimum volumes were excluded because there were strong correlations among active LA emptying fraction (LAEF), LA maximum volume and LA minimum volume (r>0.60, P<0.001). Likewise, the SRs during systole, early diastole and during atrial contraction were excluded because there were correlations among LA peak strain, SR during systole, SR during early diastole and SR during atrial contraction (r>0.50, P<0.001). Finally, prior stroke, current smoking, statin use, diuretic use, LV mass index, LA peak strain and active LAEF were tested in the multivariate logistic regression analysis. In Model 1, a history of coronary artery disease, statin use and LA peak strain at baseline were the independent predictors of new-onset AF in both groups ( Table 4 ). In Model 2, the difference over 1 year of the active LAEF was the independent predictor of new-onset AF. Coronary artery disease and change over 1 year of LA peak strain could not be included in the Model 2 because of multicollinearity through the significant association among coronary artery disease, statin use and change over 1 year of LA peak strain.
Discussion
This prospective study demonstrated that pitavastatin had a beneficial effect on LV diastolic function and LA structure and function. The present study also demonstrated that pitavastatin could prevent the development of new-onset AF in elderly hypertensive patients with established LV hypertrophy regardless of LDL-C levels.
Interpretation of Contradictory Findings in Previous Studies
Some recent studies have performed meta-analyses that showed Tables 2,3 . Effects of Statin on Prevention of New-Onset AF a protective effect of statins on the short-term risk of AF, 3,4 but those findings were not supported by meta-analysis of longerterm, large-scale trials. 14 However, the longer-term, larger-scale trials enrolled patients with a low-risk for AF, such as primary prevention patients and relatively younger patients (55-65 years old). Furthermore, in several of the longer-term trials, AF was not a specified endpoint, and this might have resulted in underestimation of the true occurrence of AF. 14 Thus, the beneficial effect of statins on AF may have been masked by underestimation of AF and/or the inclusion of patients with a low-risk for AF. In contrast, studies that focused on patients with coronary artery disease and secondary prevention of AF showed protective effects of statins on AF. 15, 16 To overcome these potential limitations, it is important to enroll patients with an increased risk of AF and to perform regular ECG examinations. Therefore, in the present study, we only enrolled subjects with HTN and LV hypertrophy, and performed monthly ECG examinations.
We recently reported that reduced LA phasic function assessed by the VVI method independently predicted the risk of new-onset AF in a prospective study, suggesting an association between LA functional remodeling and new-onset AF. 11 Other investigators reported that patients with HTN had a risk for AF, even those with a normal sized LA, because of impaired LA strain as measured by speckle-tracking methods. 17 Therefore, we focused on elderly patients with HTN to elucidate the beneficial effects of statins on new-onset AF using rigorous methods of adjudicating AF and monitoring LV and LA function.
Effects of Pitavastatin on Cardiac Structure and Function
It has been demonstrated that statins improve cardiac function through pleiotropic effects. [18] [19] [20] The mevalonate pathway that is a target in patients with HTN could be inhibited by lipophilic statins, because cardiovascular remodeling in patients with HTN causes damage to various organs. 21 In the present study, the LV mass index in the HTN patients treated with pitavastatin was significantly decreased by 6%, and this was associated with improved diastolic function despite no difference in blood pressure after 1 year. In our multivariate analysis, the difference over 1 year of the active LAEF was the independent predictor of new-onset AF. In addition, LDL-C levels at follow-up were similar in the 2 groups. These results suggest that the beneficial effects of pitavastatin on cardiac structure and function were pleiotropic effects that were independent of LDL-C levels. The findings in the present study are consistent with those from previous studies that demonstrated improved cardiac function and prognosis in chronic heart failure patients with dyslipidemia. 22,23 Furthermore, there were some additional intriguing findings in the present study. Pitavastatin improved not only cardiac function such as LAV index and E/e', but also LA phasic function such as LA SR, despite no difference in blood pressure.
Protective Effect of Pitavastatin Against New-Onset AF
We demonstrated that among the HTN patients treated with a statin there were significantly less cases of new-onset AF than among HTN patients treated without a statin over 2 years of follow-up (hazard ratio: 0.32, P=0.027). Statins have not only cholesterol-lowering effects but also pleiotropic effects on the cardiovascular system, including improvement of endothelial function, and antiinflammatory and antioxidant effects. [24] [25] [26] [27] The beneficial effect of pitavastatin on new-onset AF was independent of LDL-C levels in the present study, suggesting that pleiotropic effects on the cardiovascular system were respon-sible for preventing AF.
Cardiac hypertrophy is an independent risk factor in cardiovascular disease, and increases cardiovascular mortality. 28 There are several reports that demonstrate the effect of statins on cardiac hypertrophy. Statins prevent the development of cardiac hypertrophy through an antioxidant mechanism involving inhibition of Rac1. 29, 30 A recent study showed that pitavastatin therapy for 12-16 weeks improved LV diastolic function and a marker of oxidative stress. 31 Upstream effects of statin therapy on preventing or delaying the myocardial remodeling associated with HTN, heart failure or inflammation may influence the development of new-onset AF. 32 Therefore, we selected patients with HTN and established LV hypertrophy as the subjects of the present prospective study, based on the hypothesis that statin therapy would reduce the risk of new-onset AF in these patients.
Regarding the relationship between blood pressure and AF, HTN is the most important risk factor for AF. 33, 34 The incidence of new-onset AF in the present study was relatively lower (HTN without statin group: 13.6%/2 year and HTN with statin group: 4.5%/2 year, respectively) than expected, and in the previous study, because blood pressure was adequately controlled in both groups in the present study (HTN without statin group: 133±6/79±6 mmHg and HTN with statin group: 132±8/ 78±7 mmHg, respectively).
Clinical Implications
The present study findings suggest that pitavastatin may be recommended for elderly patients with HTN and LV hypertrophy to prevent new-onset AF and adverse cardiac remodeling. They also suggest that the indication for statins in these patients should be reconsidered in the future, because the combination of HTN and AF is associated with a particularly high stroke risk. 6
Study Limitations
First, the present study was not randomized. We divided patients with HTN into 2 groups according to the presence of dyslipidemia. Basically, a randomized study was not possible because it would have been unethical to follow-up patients with dyslipidemia without statin treatment. However, because the LDL-C levels were similar in the 2 groups after 1 year of follow-up, it would appear that the pleiotropic effects of statin therapy were responsible for the changes in AF and cardiac structure and function in patients with baseline dyslipidemia. Second, the number of incident AF cases may have been underestimated because some patients with AF had no symptoms and only AF episodes that were confirmed by ECG or Holter ECG were considered an endpoint. However, this limitation could be applied to most of the previous studies that included AF as an endpoint. Third, we performed echocardiography at 1 year of follow-up in all patients. Although some patients developed AF before this examination, other patients developed AF after this examination. The difference in the timing of echocardiography relative to the onset of AF hindered the rigorous evaluation of the effect of cardiac structure and function on the prevention of new-onset AF. Fourth, we did not compare the effect of different statins on cardiac structure and function, and the prevention of new-onset AF. Therefore, it is not clear whether other stains have the same effect as pitavastatin. Finally, a relatively small number of the patients were enrolled and the study may have been underpowered to determine the relationship between the incidence of new-onset AF and statin treatment. A study in a larger population is needed to definitively define the effects of statins on the prevention of new-onset AF. WARITA S et al.
Conclusions
Pitavastatin had a beneficial pleiotropic effect on LV diastolic function and LA structure and function in elderly patients with HTN and LV hypertrophy. Pitavastatin treatment caused regression of hypertrophy that was independent of blood pressure, and this may be associated with a lower incidence of new-onset AF.
